Compound preparation microneedle as well as preparation method and application thereof

By designing hyaluronic acid/PVP microneedle loaded with tranexamic acid, vitamin C and reduced glutathione, the problem of cumbersome and low efficiency of microneedle technology is solved, and the efficient treatment of chloasma is achieved, and the simplification of the Procedures and improve treatment efficiency.

CN118948737APending Publication Date: 2024-11-15WUXI MEILING BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411051081.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing microneedle technology is used to treat chloasma with complicated procedures, and the traditional local injection and microneedle technology combined with external application methods have problems of difficulty and low efficiency.

Method used

Design a hyaluronic acid/PVP microneedle, loaded with tranexamic acid, vitamin C and reduced glutathione, and prepare compound preparation microneedle by oscillation and ultrasonic dissolution, simplifying the operation steps and improving drug penetration and release efficiency.

Benefits of technology

It achieves efficient penetration and rapid release of drugs, significantly shortens dosing time, simplifies operational steps, improves treatment efficiency and patient compliance, and provides a new skin health treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948737A_ABST
    Figure CN118948737A_ABST
Patent Text Reader

Abstract

The invention discloses a compound preparation microneedle as well as a preparation method and application thereof. The compound preparation microneedle disclosed by the invention is prepared through a pouring method by utilizing the dissolvability of hyaluronic acid and polyvinylpyrrolidone. And finally, the microneedle patch which has certain mechanical strength and biocompatibility and is formed by connecting a plurality of micron-sized fine needle tips on the base in an array manner is formed. The formed microneedle can penetrate through the surface layer of the skin, tranexamic acid, vitamin C and reduced glutathione are transferred to the basal layer of the skin through one-time operation, then tranexamic acid is competitively combined with tyrosinase, the activity of the tyrosinase is inhibited, and therefore formation of melanin is reduced; the vitamin C inhibits the formation of melanin by reducing the formation of o-quinone and reducing oxidized melanin; the reduced glutathione is used as an antioxidant component, can inhibit the generation of free radicals, helps to stabilize the skin and restore the skin whiteness, can be used for treating chloasma, and provides a new solution for the field of skin health treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microneedle drug delivery, and in particular to a compound preparation microneedle and a preparation method and application thereof. Background Art

[0002] Melasma is a common hyperpigmented skin disease that progresses slowly without causing any discomfort. It is often symmetrically distributed on the cheeks, forehead, nose, lips, and around the eyes. It is irregular in shape and dark brown or light brown in color. There are many ways to treat melasma, including oral and topical medications, photoelectric projects, fruit acid peels, and whitening injections.

[0003] Tranexamic acid (TXA) is a protease inhibitor. On the one hand, it interferes with the interaction between melanocytes and keratinocytes by inhibiting the plasminogen-fibrinolytic system, reduces the activity of tyrosinase, and thus inhibits the formation of melanin. On the other hand, tranexamic acid has a similar chemical structure to tyrosine and can competitively bind to tyrosinase, inhibiting the activity of tyrosinase, thereby reducing the formation of melanin and ultimately playing a role in treating chloasma. Vitamin C (Vit C) is a polyhydroxy compound with strong reducing properties. It can effectively inhibit the oxidation of dopa, reduce the melanin already present in the skin to a colorless substance, and can also convert melanin into a water-soluble colloidal substance. Glutathione (GSH) is an antioxidant that has the effects of anti-oxidation, eliminating free radicals, and inhibiting the activity of tyrosinase, thereby reducing the formation of melanin and its deposition in the skin.

[0004] Microneedles are an emerging transdermal technology that is widely used in the medical field, such as drug delivery, wound healing, vaccination, interstitial fluid extraction and biomarker detection, and beauty. Hyaluronic acid (HA) is one of the main components of the skin. It has excellent biocompatibility and in vivo degradability and is one of the natural polymer materials for preparing soluble microneedles. Polyvinyl pyrrolidone (PVP) has excellent physiological inertness, does not participate in human metabolism, and has excellent biocompatibility. It does not cause any irritation to the skin. Medical grade PVP is one of the three major new pharmaceutical excipients advocated internationally. Microneedles prepared with hyaluronic acid / PVP have high mechanical strength and can penetrate the surface of the skin.

[0005] Currently, microneedle technology combined with topical application of tranexamic acid is often used in clinical treatment of chloasma, but the operation steps are relatively cumbersome. Therefore, a new hyaluronic acid / PVP microneedle of tranexamic acid combined with vitamin C / reduced glutathione for the treatment of chloasma was designed and prepared. The microneedle has simple operation, significant effect and strong practical value. Summary of the invention

[0006] In view of the deficiencies of the prior art, the present invention provides a compound preparation microneedle and its preparation method and application. Based on the good biosafety and strong mechanical properties of hyaluronic acid and PVP, combined with the efficacy of tranexamic acid, vitamin C and reduced glutathione in inhibiting the formation of melanin, the present invention designs and prepares a hyaluronic acid / PVP microneedle, which is effectively loaded with tranexamic acid, vitamin C and reduced glutathione, and can treat chloasma in a targeted manner, providing a new solution for skin health.

[0007] The technical solution of the present invention is as follows:

[0008] A method for preparing a composite preparation microneedle, characterized in that the preparation method comprises the following steps:

[0009] (1) adding hyaluronic acid, tranexamic acid, vitamin C and reduced glutathione into water, shaking and ultrasonically dissolving to obtain a needle tip solution;

[0010] (2) adding hyaluronic acid and polyvinyl pyrrolidone into water, shaking, and ultrasonically dissolving to obtain a base solution;

[0011] (3) adding the needle tip solution obtained in step (1) to the microneedle array mold, centrifuging to fill the needle tip solution in the needle tip part of the microneedle array mold, and then adding the base solution obtained in step (2), centrifuging again, drying, and demolding to obtain the composite preparation microneedles.

[0012] Furthermore, in step (1), the concentration of hyaluronic acid in water is 150-400 mg / mL; the concentration of tranexamic acid in water is 25-75 mg / mL; the concentration of vitamin C in water is 15-50 mg / mL; and the concentration of reduced glutathione in water is 10-40 mg / mL.

[0013] Furthermore, in step (1), the oscillation speed is 800-1000 rpm, and the time is 1-2 min; the ultrasonic power is 80-100 W, and the time is 20-30 min.

[0014] Furthermore, in step (2), the concentration of the hyaluronic acid in water is 150-400 mg / mL; the concentration of the polyvinyl pyrrolidone in water is 150-400 mg / mL.

[0015] Furthermore, in step (2), the oscillation speed is 800-1000 rpm, and the time is 1-2 min; the ultrasonic power is 80-100 W, and the time is 20-30 min.

[0016] Furthermore, in step (3), the centrifugal speed is 4000-4200 rpm and the time is 20-25 min.

[0017] Furthermore, in step (3), the drying temperature is 20-25° C. and the drying time is 18-24 hours.

[0018] A composite preparation microneedle prepared by the preparation method.

[0019] A compound preparation microneedle prepared by the preparation method described in claim 1 or an application of the compound preparation microneedle.

[0020] Furthermore, the compound preparation microneedle is used in the preparation of a product for treating chloasma.

[0021] The beneficial technical effects of the present invention are:

[0022] The compound preparation microneedle developed by the present invention fully utilizes the advantages of biological safety and mechanical strength of hyaluronic acid and PVP, innovatively loads multiple active ingredients such as tranexamic acid, vitamin C and reduced glutathione, and at the same time, based on the optimization of the relative dosage of the effective components, improves the freckle removal effect of the compound preparation microneedle. This preparation design aims to achieve efficient penetration and release of drugs through microneedle technology, providing a new treatment strategy for skin health.

[0023] The compound preparation microneedle developed by the present invention is simpler to operate than the traditional method of administering tranexamic acid by local injection, and does not require professional personnel to operate. Compared with the method that requires two-step operation for microneedle technology combined with external application of tranexamic acid, the tranexamic acid in the compound preparation microneedle developed by the present invention can directly reach the basal layer of the skin with hyaluronic acid / PVP microneedle, simplifying the operation steps, and can quickly diffuse and play a role; compared with the single component of tranexamic acid loaded by microneedle, the vitamin C and glutathione in the present invention can synergize with tranexamic acid to make it more effective and achieve the freckle removal effect faster. The present invention optimizes the amount of hyaluronic acid in the needle tip part, and the needle body of the prepared compound preparation microneedle is complete, and has good mechanical strength, and at the same time, the viscosity is suitable, the dissolution efficiency is high, and it is easy to absorb, which ensures the rapid release of the active component. Therefore, compared with the treatment methods of local injection of tranexamic acid, microneedle technology combined with external tranexamic acid or microneedle loading single-component tranexamic acid, the compound preparation microneedle developed by the present invention not only greatly shortens the administration time of external medications, significantly improves drug concentration, but also greatly simplifies the operation steps, reduces the difficulty of operation, and makes the treatment process more convenient and efficient. At the same time, the microneedle preparation significantly enhances the therapeutic effect, makes the therapeutic effect more significant and rapidly manifests, and then improves the patient's treatment compliance. Therefore, the compound preparation microneedle developed by the present invention shows excellent application prospects in the treatment of chloasma, and provides a new solution for the field of skin health treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The present invention is a flow chart of the preparation of the composite preparation microneedles.

[0025] Figure 2 This is the SEM image of the composite preparation microneedle prepared in Examples 1-3 of the present invention.

[0026] In the figure: A, electron micrograph of the microneedle of the compound preparation prepared in Example 1 at a scale of 200 μm; B, electron micrograph of the microneedle of the compound preparation prepared in Example 1 at a scale of 50 μm; C, electron micrograph of the microneedle of the compound preparation prepared in Example 2 at a scale of 50 μm; D, electron micrograph of the microneedle of the compound preparation prepared in Example 3 at a scale of 200 μm; E, electron micrograph of the microneedle of the compound preparation prepared in Example 3 at a scale of 50 μm.

[0027] Figure 3 Graph showing the relationship between displacement and bearing capacity of the microneedles of the composite preparations prepared in Examples 1-3 of the present invention.

[0028] In the figure: A, displacement and bearing capacity relationship diagram of the microneedle of the compound preparation prepared in Example 1; B, displacement and bearing capacity relationship diagram of the microneedle of the compound preparation prepared in Example 2; C, displacement and bearing capacity relationship diagram of the microneedle of the compound preparation prepared in Example 3.

[0029] Figure 4 This is a graph showing the in vitro penetration rate of the hyaluronic acid microneedles prepared in Examples 1-3 of the present invention after being penetrated into pig skin.

[0030] In the figure: A, in vitro penetration rate of microneedles of the compound preparation prepared in Example 1; B, in vitro penetration rate of microneedles of the compound preparation prepared in Example 2; C, in vitro penetration rate of microneedles of the compound preparation prepared in Example 3.

[0031] Figure 5 This is a diagram showing the penetration and absorption effect of the microneedles of the composite preparation prepared in Example 1 of the present invention.

[0032] Figure 6 This is a diagram showing the penetration and absorption effect of the microneedles of the composite preparation prepared in Example 2 of the present invention.

[0033] Figure 7 This is a diagram showing the penetration and absorption effect of the microneedles of the composite preparation prepared in Example 3 of the present invention.

[0034] Figure 8 HE staining of the composite preparation prepared in Examples 1-3 of the present invention after microneedle puncture into pig skin.

[0035] In the figure: A, HE staining of the microneedle of the compound preparation prepared in Example 1 after piercing the pig skin; B, HE staining of the microneedle of the compound preparation prepared in Example 2 after piercing the pig skin; C, HE staining of the microneedle of the compound preparation prepared in Example 3 after piercing the pig skin.

[0036] Fig. 9 This is a graph showing the effects of the compound preparation microneedles prepared in Examples 1-3 of the present invention and the preparation microneedles prepared in Comparative Example 4 on B16 cell activity.

[0037] Fig.10 This is a diagram showing the effects of the composite preparation microneedles prepared in Example 1 of the present invention and the preparation microneedles prepared in Comparative Example 4 on melanin production.

[0038] Fig.11 This is a graph showing the effects of the compound preparation microneedles prepared in Examples 1-3 of the present invention and the preparation microneedles prepared in Comparative Example 4 on L929 cell activity.

[0039] Fig.12 This is a photo of the composite preparation microneedle prepared in Comparative Example 5 of the present invention. DETAILED DESCRIPTION

[0040] The present invention is described in detail below in conjunction with the accompanying drawings and embodiments.

[0041] In the following examples, the brand of polyvinyl pyrrolidone (PVP K54-K65) is Anaiji, and the product number is A050762; hyaluronic acid (molecular weight Mw=10 kDa) is purchased from Dalian Meilun Biotechnology Co., Ltd., and the product number is MB7392.

[0042] Example 1

[0043] A compound preparation microneedle, the preparation method of which is as follows:

[0044] (1) 250 mg of hyaluronic acid, 50 mg of tranexamic acid, 30 mg of vitamin C, and 20 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min, and then sonicated at 90 W for 25 min to fully dissolve them to obtain a needle tip solution.

[0045] (2) 250 mg of hyaluronic acid and 250 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min using a vortex oscillator, and then sonicated at 90 W for 25 min to fully dissolve them, thereby obtaining a base solution.

[0046] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4200 rpm for 20 min to fill the needle tip solution in the needle tip part of the PDMS mold. The excess solution is removed after centrifugation; 100 μL of base solution is then added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 25°C for 20 h, and finally demolded to obtain a composite preparation microneedle.

[0047] Figure 2 A and 2B are scanning electron microscope images of the microneedles of the composite preparation prepared in Example 1 of the present invention. Figure 2 Figures A and B in the figure show that each microneedle is conical with a base diameter of 150 μm and a height of 650 μm.

[0048] Example 2

[0049] A compound preparation microneedle, the preparation method of which is as follows:

[0050] (1) 150 mg of hyaluronic acid, 25 mg of tranexamic acid, 15 mg of vitamin C, and 10 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min, and then sonicated at 90 W for 25 min to fully dissolve them to obtain a needle tip solution.

[0051] (2) 250 mg of hyaluronic acid and 250 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min using a vortex oscillator, and then sonicated at 90 W for 25 min to fully dissolve them, thereby obtaining a base solution.

[0052] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4200 rpm for 20 min to fill the needle tip solution in the needle tip part of the PDMS mold. The excess solution is removed after centrifugation; 100 μL of base solution is then added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 25°C for 20 h, and finally demolded to obtain a composite preparation microneedle.

[0053] Figure 2 C is a scanning electron microscope image of the microneedle of the composite preparation prepared in Example 1 of the present invention. Figure 2 Figure C in Figure 2 shows that each microneedle is conical with a base diameter of 150 μm and a height of 650 μm.

[0054] Example 3

[0055] A compound preparation microneedle, the preparation method of which is as follows:

[0056] (1) 400 mg of hyaluronic acid, 75 mg of tranexamic acid, 50 mg of vitamin C, and 40 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min, and then sonicated at 90 W for 25 min to fully dissolve them to obtain a needle tip solution.

[0057] (2) 250 mg of hyaluronic acid and 250 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min using a vortex oscillator, and then sonicated at 90 W for 25 min to fully dissolve them, thereby obtaining a base solution.

[0058] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4200 rpm for 20 min to fill the needle tip solution in the needle tip part of the PDMS mold. The excess solution is removed after centrifugation; 100 μL of base solution is then added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 25°C for 20 h, and finally demolded to obtain a composite preparation microneedle.

[0059] Figure 2 D and 2E are scanning electron microscope images of the microneedles of the composite preparation prepared in Example 1 of the present invention. Figure 2 Figures D and E in the figure show that each microneedle is conical with a base diameter of 150 μm and a height of 650 μm.

[0060] Example 4

[0061] A compound preparation microneedle, the preparation method of which is as follows:

[0062] (1) 250 mg of hyaluronic acid, 50 mg of tranexamic acid, 30 mg of vitamin C, and 20 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 800 rpm for 2 min, and then sonicated at 80 W for 30 min to fully dissolve them to obtain a needle tip solution.

[0063] (2) 400 mg of hyaluronic acid and 400 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 800 rpm for 2 min, and then ultrasonicated at 80 W for 30 min to fully dissolve them, thereby obtaining a base solution.

[0064] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4000 rpm for 25 min to fill the needle tip solution in the needle tip part of the PDMS mold. After centrifugation, excess solution is removed; then 100 μL of base solution is added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 20°C for 24 h, and finally demolded to obtain a composite preparation microneedle.

[0065] Example 5

[0066] A compound preparation microneedle, the preparation method of which is as follows:

[0067] (1) 250 mg of hyaluronic acid, 50 mg of tranexamic acid, 30 mg of vitamin C, and 20 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 1000 rpm for 1 min, and then ultrasonicated at 100 W for 20 min to fully dissolve them to obtain a needle tip solution.

[0068] (2) 150 mg of hyaluronic acid and 150 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 1000 rpm for 1 min, and then ultrasonicated at 100 W for 20 min to fully dissolve them, thereby obtaining a base solution.

[0069] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4200 rpm for 20 min to fill the needle tip solution in the needle tip part of the PDMS mold. The excess solution is removed after centrifugation; 100 μL of base solution is then added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 25°C for 18 h, and finally demolded to obtain a composite preparation microneedle.

[0070] Comparative Example 1

[0071] Comparative Example 1 prepares hyaluronic acid / PVP microneedles loaded with rhodamine 6G, and its preparation method is basically the same as that of Example 1, except that 80 mg of rhodamine 6G is used as a simulated drug in the preparation of the needle tip solution of Comparative Example 6 to replace the active substances of 50 mg of tranexamic acid, 30 mg of vitamin C and 20 mg of reduced glutathione in Example 1.

[0072] Comparative Example 2

[0073] Comparative Example 2 prepared hyaluronic acid / PVP microneedles loaded with rhodamine 6G, and its preparation method was basically the same as that of Example 2, except that 80 mg of rhodamine 6G was used as a simulated drug in the preparation of the needle tip solution of Comparative Example 7 to replace the active substances of 25 mg of tranexamic acid, 15 mg of vitamin C and 10 mg of reduced glutathione in Example 2.

[0074] Comparative Example 3

[0075] Comparative Example 3 prepared hyaluronic acid / PVP microneedles loaded with rhodamine 6G, and its preparation method was basically the same as that of Example 1, except that 80 mg of rhodamine 6G was used as a simulated drug in the preparation of the needle tip solution of Comparative Example 8 to replace 75 mg of tranexamic acid, 50 mg of vitamin C and 40 mg of reduced glutathione in Example 3.

[0076] Comparative Example 4

[0077] Comparative Example 4 is a comparative example of Example 1, except that Comparative Example 4 is a preparation microneedle loaded with tranexamic acid alone, and the active ingredient of the preparation microneedle in Comparative Example 4 is only 50 mg of tranexamic acid, and does not contain vitamin C and reduced glutathione.

[0078] Comparative Example 5

[0079] A compound preparation microneedle, the preparation method of which is as follows:

[0080] (1) 100 mg of hyaluronic acid, 50 mg of tranexamic acid, 30 mg of vitamin C, and 20 mg of reduced glutathione were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min, and then sonicated at 90 W for 25 min to fully dissolve them to obtain a needle tip solution.

[0081] (2) 100 mg of hyaluronic acid and 250 mg of polyvinyl pyrrolidone were added to 1 mL of ultrapure water, vortexed at 900 rpm for 2 min, and then sonicated at 90 W for 25 min to fully dissolve them, thereby obtaining a base solution.

[0082] (3) According to Figure 1 The process is as follows: 100 μL of needle tip solution is injected into the PDMS mold, and the mold is centrifuged at 4200 rpm for 20 min to fill the needle tip solution in the needle tip part of the PDMS mold. The excess solution is removed after centrifugation; 100 μL of base solution is then added to the base layer of the PDMS mold, and the mold is placed in a centrifuge again and centrifuged at 4200 rpm for 20 min to fill the base solution in the base part of the PDMS mold; the mold is dried at 25°C for 20 h, and finally demolded to obtain a composite preparation microneedle.

[0083] Fig.12 Photos of the composite preparation microneedles prepared in Comparative Example 5 of the present invention, Fig.12 The results showed that a large number of microneedles were broken and the needle bodies were incomplete.

[0084] Test Case

[0085] (1) Mechanical properties test of compound preparation microneedles

[0086] This test experiment involves the mechanical strength test of the microneedle of the compound preparation, and the operation method is as follows: the microneedle is placed on the flat rigid surface of the stainless steel substrate with the needle tip facing upward, and the sensor probe approaches the microneedle in the vertical direction. At the moment the needle tip touches the probe, the probe begins to detect the change in force when the microneedle is squeezed. Figure 3 The mechanical properties test results of the composite preparation microneedles prepared in Examples 1-3 of the present invention are shown in FIG. Figure 3 The results show that the microneedles of the composite preparation prepared by the present invention have certain mechanical properties, which enable the microneedles to penetrate the skin in a tiny space and accurately control drug delivery.

[0087] Fresh pigskin purchased from a local farmers' market was cut into pieces of about 2 cm × 2 cm in size, one of which was taken and laid flat on the laboratory table, and the microneedles of the composite preparation prepared in Examples 1-3 of the present invention were vertically inserted into the pigskin, and then the microneedles were immediately pulled out and placed in a 15 mL centrifuge tube filled with 4% paraformaldehyde for fixation; HE staining of the tissue sections was then performed to observe the changes in the epidermal tissue of the pigskin after the microneedles were inserted. The results are as follows: Figure 8 As shown. Figure 8 The results show that the microneedles of the composite preparations prepared in Examples 1-3 of the present invention can penetrate into the surface layer of pig skin and have good mechanical strength.

[0088] (2) In vitro penetration rate and transdermal absorption test of microneedles of compound preparations

[0089] In vitro penetration rate test:

[0090] Fresh pig skin purchased from a local farmers' market was cut into pieces of about 2 cm × 2 cm in size. One piece was taken and laid flat on the laboratory table. Then the hyaluronic acid / PVP microneedles loaded with rhodamine 6G in comparative example 1-3 were vertically inserted into the pig skin. The microneedles were removed after 3 minutes. The ratio of the number of red dots on the pig skin to the number of microneedle bodies was calculated, and finally the in vitro penetration rate of the hyaluronic acid / PVP microneedles was obtained. The results are shown in Figure 2. Figure 4 As shown. Figure 4 The results show that, through the pig skin simulation skin penetration condition, the hyaluronic acid / PVP microneedles prepared by the present invention have a penetration rate of 100% in vitro and have sufficient mechanical strength.

[0091] Transdermal absorption test:

[0092] Fresh pig skin purchased from the local farmer's market was cut into pieces of about 2cm×2cm in size. One piece was taken and laid flat on the laboratory table. Then the hyaluronic acid / PVP microneedles loaded with rhodamine 6G prepared in comparative examples 1-3 of the present invention were vertically inserted into the pig skin. The microneedles were removed after 3 minutes. The excess red rhodamine 6G on the surface of the pig skin was wiped off with a wet cotton ball, and then the pig skin was placed under a laser confocal microscope. When the excitation light is 532nm, find the point with the brightest fluorescence intensity; then adjust the microscope on the same Z axis to find the critical point where the fluorescence intensity becomes the weakest; then, take fluorescence images every 10μm between the two points to obtain a series of images simulating the depth of the skin that the drug rhodamine 6G can reach. The results are as follows: Figure 5-7 As shown. Figure 5-7 The results show that the hyaluronic acid microneedles loaded with rhodamine 6G can reach a depth of at least 210 μm in the skin, which is enough to penetrate the surface of the skin.

[0093] (3) The compound preparation microneedle inhibits the production of melanin

[0094] Mouse melanoma cells B16 were used as model cells to conduct experiments on the efficacy of compound preparation microneedles in inhibiting melanin production. Mouse melanoma cells B16 were inoculated in 96-well plates, with 10 5 After the cells adhered to the wall, they were washed once with PBS. Five groups were set up, and the treatment of each group was as follows

[0095] Contral group: add 100 μL fresh DMEM medium;

[0096] TXA group: 100 μL of DMEM medium dissolved with one single tranexamic acid-loaded preparation microneedle prepared in Comparative Example 4 of the present invention was added;

[0097] TXA+VitC+GSH-1 group: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 1 of the present invention was added;

[0098] TXA+VitC+GSH-2 group: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 2 of the present invention was added;

[0099] TXA+VitC+GSH-3 group: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 3 of the present invention was added;

[0100] After the above treatment, the cells were cultured at 37°C and 5% CO2 for 24 h, and then 10 μL of CCK8 solution was added to each well. After incubation for 1.5 h, the cell viability was measured at 450 nm using an ELISA reader. The wells with only the culture medium added were the control group, and the cell viability of the remaining groups was calculated using the normalization method. The results are shown in Figure 2. Fig. 9 As shown. Fig. 9 As can be seen from the results in the figure, both the DMEM culture medium of the microneedles of the preparation loaded with tranexamic acid alone and the microneedles of the compound preparation prepared by the present invention can kill melanoma cells B16 and promote their apoptosis, and the effect of the microneedles of the compound preparation prepared by the present invention on killing melanoma cells B16 is more significant than that of the microneedles of the preparation loaded with tranexamic acid alone.

[0101] To measure melanin content, 0.5 × 10 cells / mL of melanin were cultured in DMEM without phenol red in 6-well plates. 5 B16 cells were cultured at a density of 10 cells / well. After they adhered to the wall, three groups were set up. The treatment of each group was as follows

[0102] Contral group: add 100 μL fresh DMEM medium;

[0103] TXA group: 100 μL of DMEM medium dissolved with one single tranexamic acid-loaded preparation microneedle prepared in Comparative Example 4 of the present invention was added;

[0104] TXA+VitC+GSH group: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 1 of the present invention was added;

[0105] After the above treatment, the cells were co-cultured at 37°C and 5% CO2 for 48 h, centrifuged at 13,000 rpm for 4 min, and the cell-free culture medium was collected in a 96-well plate. The extracellular melanin content was quantified at a wavelength of 490 nm using an ELISA reader. The wells without microneedles were used as the control group, and the extracellular melanin content of the other groups was calculated using the normalization method. The results are shown in Figure 2. Fig.10 As shown. Fig.10 The results show that the compound preparation microneedles loaded with tranexamic acid / vitamin C / reduced glutathione prepared by the present invention are significantly better than the microneedles of the preparation loaded with tranexamic acid alone in clearing and inhibiting melanin production, indicating that the compound preparation microneedles loaded with tranexamic acid / vitamin C / reduced glutathione have a good clearing effect on melanin and can be used to treat chloasma.

[0106] (4) In vitro biosafety of compound microneedle preparations

[0107] Mouse skin fibroblast L929 was used as a model cell to conduct an in vitro biosafety experiment on the microneedle compound preparation. Mouse fibroblast L929 was inoculated into a 96-well plate, with 10 5 After the cells adhered to the wall, they were washed once with PBS. Five groups were set up.

[0108] Contral group: add 100 μL fresh DMEM medium;

[0109] TXA group / 1h: 100 μL of DMEM medium dissolved with one single tranexamic acid loaded preparation microneedle prepared in Comparative Example 4 of the present invention was added, and the microneedle dissolution time was 1h. After the dissolution was completed, it was used for culturing L929 cells;

[0110] TXA group / 16h: 100 μL of DMEM medium dissolved with one single tranexamic acid loaded preparation microneedle prepared in Comparative Example 4 of the present invention was added, and the microneedle dissolution time was 16h. After the dissolution was completed, it was used for culturing L929 cells;

[0111] TXA+VitC+GSH-1 group / 1h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 1 of the present invention was added, and the microneedle dissolution time was 1h. After the dissolution was completed, the microneedle was used for culturing L929 cells;

[0112] TXA+VitC+GSH-1 group / 16h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 1 of the present invention was added, and the microneedle dissolution time was 16h. After the dissolution was completed, it was used for culturing L929 cells;

[0113] TXA+VitC+GSH-2 group / 1h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 2 of the present invention was added, and the microneedle dissolution time was 1h. After the dissolution was completed, it was used for culturing L929 cells;

[0114] TXA+VitC+GSH-2 group / 16h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 2 of the present invention was added, and the microneedle dissolution time was 16h. After the dissolution was completed, it was used for culturing L929 cells;

[0115] TXA+VitC+GSH-3 group / 1h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 3 of the present invention was added, and the microneedle dissolution time was 1h. After the dissolution was completed, it was used for culturing L929 cells;

[0116] TXA+VitC+GSH-3 group / 16h: 100 μL of DMEM medium dissolved with one microneedle of the composite preparation prepared in Example 3 of the present invention was added, and the microneedle dissolution time was 16h. After the dissolution was completed, it was used for culturing L929 cells;

[0117] After the above treatment, the cells were cultured at 37°C and 5% CO2 for 24 hours, and then 10 μL of CCK8 solution was added to each well. After incubation for 1.5 hours, the cell viability was measured at a wavelength of 450 nm using an ELISA reader. When the dissolution time was 1 hour, the microneedles were not completely dissolved, which represented short-term contact with the skin. When the dissolution time was 16 hours, the microneedles were completely dissolved, which represented long-term contact with the skin. The wells where only the culture medium was added were the control group. The normalization method was used to calculate the viability of the remaining cells. The results are shown in Figure 2. Fig.10 As shown. Fig.10 The results show that the single preparation microneedles loaded with tranexamic acid and the compound preparation microneedles did not have a negative impact on the cell viability of mouse fibroblasts, which fully proves that the compound preparation microneedles loaded with tranexamic acid / vitamin C / reduced glutathione prepared by the present invention have good in vitro biosafety.

[0118] The above is only a preferred embodiment of the present invention, and the present invention is not limited to the above embodiments. It is understood that other improvements and changes directly derived or associated by those skilled in the art without departing from the spirit and concept of the present invention should be considered to be included in the protection scope of the present invention.

Claims

1. A method for preparing a composite preparation microneedle, characterized in that: The preparation method comprises the following steps: (1) adding hyaluronic acid, tranexamic acid, vitamin C and reduced glutathione into water, shaking and ultrasonically dissolving to obtain a needle tip solution; (2) adding hyaluronic acid and polyvinyl pyrrolidone into water, shaking, and ultrasonically dissolving to obtain a base solution; (3) adding the needle tip solution obtained in step (1) to the microneedle array mold, centrifuging to fill the needle tip solution in the needle tip part of the microneedle array mold, and then adding the base solution obtained in step (2), centrifuging again, drying, and demolding to obtain the composite preparation microneedles.

2. The preparation method according to claim 1, characterized in that: In step (1), the concentration of hyaluronic acid in water is 150-400 mg / mL; the concentration of tranexamic acid in water is 25-75 mg / mL; the concentration of vitamin C in water is 15-50 mg / mL; and the concentration of reduced glutathione in water is 10-40 mg / mL.

3. The preparation method according to claim 1, characterized in that: In step (1), the oscillation speed is 800-1000 rpm, and the time is 1-2 min; the ultrasonic power is 80-100 W, and the time is 20-30 min.

4. The preparation method according to claim 1, characterized in that: In step (2), the concentration of the hyaluronic acid in water is 150-400 mg / mL; the concentration of the polyvinyl pyrrolidone in water is 150-400 mg / mL.

5. The preparation method according to claim 1, characterized in that: In step (2), the oscillation speed is 800-1000 rpm, and the time is 1-2 min; the ultrasonic power is 80-100 W, and the time is 20-30 min.

6. The preparation method according to claim 1, characterized in that: In step (3), the centrifugal speed is 4000-4200 rpm and the time is 20-25 min.

7. The preparation method according to claim 1, characterized in that: In step (3), the drying temperature is 20-25°C and the drying time is 18-24h.

8. A composite preparation microneedle prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the compound preparation microneedle prepared by the preparation method according to any one of claims 1 to 7 or the compound preparation microneedle according to claim 8.

10. The use according to claim 9, characterized in that: The application of the compound preparation microneedle in preparing a product for treating chloasma.

Citation Information

Cited By

  • Soluble microneedle patch for skin tumor as well as preparation method and application of soluble microneedle patch

    CN121243043A